Search Results
Dec 09, 2025, 07:44 ET Unprecedented results from the Phase 3 MajesTEC-3 study support TECVAYLI® plus DARZALEX FASPRO® as a potential standard of care as early as second line for patients with relapsed/refractory multiple myeloma
Results show an 83% reduction in the risk of disease progression or death compared to standard regimens at nearly three-years follow-up (hazard ratio [HR], 0.17; 95 percent confidence interval [CI], 0.12-0.23; P<0.0001).1 Ninety-one percent of patients who were progression-free at six months
More news about: Johnson & Johnson
Dec 09, 2025, 07:30 ET Lilly's Jaypirca (pirtobrutinib) significantly improved progression-free survival, reducing the risk of progression or death by 80%, versus chemoimmunotherapy in patients with treatment-naïve CLL/SLL
(CLL/SLL) without 17p deletions. Pirtobrutinib met its primary endpoint demonstrating a reduction in the risk of disease progression or death by 80% (HR=0.20 [95% CI, 0.11-0.37]; p<0.0001).
More news about: Eli Lilly and Company
Dec 09, 2025, 04:00 ET ezW2 2025 Now Offering W2 and 1099 E-File Service Add-On!
Also available is ezW2 2025 Enterprise Multiple-user Network Version for Windows, starting at $119 for two installations.Accountants, HR teams, e-commerce businesses, and SMBs alike continue to choose ezW2 for its exceptional quality and affordable pricing.Comprehensive
More news about: Halfpricesoft.com
Dec 09, 2025, 00:00 ET Latest Women in the Workplace Report Reveals Corporate America Risks Rolling Back Progress for Women
we collected pipeline data from 124 organizations employing approximately 3 million people, surveyed 70 companies on their HR policies and practices, conducted interviews with 62 HR executives, and collected insights from 9,500+ employees.ABOUT MCKINSEY & COMPANYMcKinsey is a
More news about: LeanIn.Org
Dec 08, 2025, 21:02 ET Significant Improvement in Quality of Life Reported in Updated HARMONi-6 Data for Ivonescimab at ESMO Asia
maintain better overall health status. Time to deterioration in "Global Health Status/Quality of Life" was meaningfully delayed in the ivonescimab arm (HR = 0.94), indicating a trend toward reduced risk of QoL worsening versus the control group.The ivonescimab-based regimen met the primary PFS
More news about: Akeso, Inc.
Dec 08, 2025, 15:17 ET Le groupe Menarini présente les données de la phase 2 sur l'association d'Elacestrant (ORSERDU®) chez des patientes atteintes d'un cancer du sein métastatique (mBC) ER+, HER2- lors du 2025 San Antonio Breast Cancer Symposium
l'elacestrant associé au trastuzumab deruxtecan chez des patientes atteintes d'un cancer du sein métastatique avec inhibiteur CDK4/6 et résistant à l'endocrine, HR+/HER2-faible ou HER2-ultralowNuméro de l'abrégé : 2119Date et heure de la présentation : Vendredi 12 décembre 2025, 12h30
More news about: Menarini Industrie Farmaceutiche Riunite
Dec 08, 2025, 15:06 ET Why AI Investments Stall: New Guidance on Data Operating Models Published by Info-Tech Research Group
Info-Tech Research Group is one of the world's leading and fastest-growing research and advisory firms, serving over 30,000 IT, HR, and marketing professionals around the globe. As a trusted product and service leader, the company delivers unbiased, highly relevant research and industry-leading
More news about: Info-Tech Research Group
Dec 08, 2025, 14:47 ET Menarini Group präsentiert Daten zur Phase-2-Kombination von Elacestrant (ORSERDU®) bei Patientinnen mit ER+, HER2- metastasiertem Brustkrebs (mBC) auf dem San Antonio Breast Cancer Symposium 2025
Präsentation: ERADICATE: Eine Phase-Ib/II-Studie von Elacestrant plus Trastuzumab-Deruxtecan bei Patientinnen mit CDK4/6-Inhibitor- und endokrinresistentem HR+/HER2-armem oder HER2-ultralarmem metastasiertem BrustkrebsAbstract Number: 2119Datum und Uhrzeit der Präsentation: Freitag,
More news about: Menarini Industrie Farmaceutiche Riunite
Dec 08, 2025, 14:11 ET Healthcare CIOs Urged to Build AI-Driven, Technology-First Action Plans as Uncertainty Mounts, Says Info-Tech Research Group
Info-Tech Research Group is one of the world's leading and fastest-growing research and advisory firms, serving over 30,000 IT, HR, and marketing professionals around the globe. As a trusted product and service leader, the company delivers unbiased, highly relevant research and industry-leading
More news about: Info-Tech Research Group
Dec 08, 2025, 13:41 ET Menarini Group Presents Elacestrant (ORSERDU®) Phase 2 Combination Data in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the 2025 San Antonio Breast Cancer Symposium
Llombart-CussacPresentation Title: ERADICATE: A phase Ib/II study of elacestrant plus trastuzumab deruxtecan in patients with CDK4/6 inhibitor and endocrine-resistant HR+/HER2-low or HER2-ultralow metastatic breast cancerAbstract Number: 2119Presentation Date & Time: Friday, December
More news about: Menarini Industrie Farmaceutiche Riunite
Dec 08, 2025, 13:30 ET Menarini Group Presents Elacestrant (ORSERDU®) Phase 2 Combination Data in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the 2025 San Antonio Breast Cancer Symposium
Llombart-CussacPresentation Title: ERADICATE: A phase Ib/II study of elacestrant plus trastuzumab deruxtecan in patients with CDK4/6 inhibitor and endocrine-resistant HR+/HER2-low or HER2-ultralow metastatic breast cancerAbstract Number: 2119Presentation Date & Time: Friday, December
More news about: Menarini Industrie Farmaceutiche Riunite
Dec 08, 2025, 11:30 ET Tammi Wortham, SVP of HR at Sun Life U.S., receives Icon Award from Boston Business Journal
WELLESLEY, Mass., Dec. 8, 2025 /PRNewswire/ -- Tammi Wortham, senior vice president of Human Resources (HR) at Sun Life U.S., has received an Icon Award from the Boston Business Journal (BBJ). The Icon Awards are part of the BBJ's Women Who Mean Business recognition
More news about: Sun Life U.S.
Dec 08, 2025, 11:28 ET INE Earns G2 Winter 2026 Badges Across Global Markets
lab setup, and that INE certificates, such as eJPT and eWPTX, have good value in the cybersecurity industry as they are known and valued by technical HR recruiters."These G2 badges validate our mission to deliver world-class cybersecurity and technical training that keeps pace with evolving technologies
More news about: INE
Dec 08, 2025, 09:00 ET House of Rose Professional Announces 2026 World Tour of Break the Ceiling Touch the Sky® Summit
editions across the Americas, Asia, the Middle East & Africa, Europe, and ANZ bringing together CEOs, C-suite executives, high-potential women leaders, HR and belonging champions, male allies, and innovators from the world's most influential organizations. The USA, UK, India, UAE, Singapore are the priority
More news about: House of Rose Professional Pte. Ltd.
Dec 08, 2025, 08:00 ET Hypershell Publishes First Consumer Exoskeleton Standards White Paper, Calling for Industry-Wide Transparency and Unified Testing Frameworks
and performance metrics, including:Clear, technically precise test definitionsReproducible protocols for VO₂, EMG, and HR testingUniform reporting formats (analogous to automotive industry metrics)Industry-wide transparency regarding firmware, hardware,
More news about: Hypershell Co., Ltd.
Dec 08, 2025, 02:30 ET The impact of avoiding recurrence: New BRAVO Study abstract at SUO 2025 demonstrates Cost Neutrality in Blue Light versus White Light Cystoscopy comparison
43%; p<0.01) and intravesical chemotherapy (49% and 28%, p<0.01), respectively.BLC use was associated with decreased risk or recurrence (HR 0.62, p<0.01)Initial total costs over 5 years were higher in the BLC group ($108,411 vs $66,734; p<0.01), with outpatient costs being
More news about: Photocure
Dec 08, 2025, 02:27 ET The impact of avoiding recurrence: New BRAVO Study abstract at SUO 2025 demonstrates Cost Neutrality in Blue Light versus White Light Cystoscopy comparison
43%; p<0.01) and intravesical chemotherapy (49% and 28%, p<0.01), respectively.BLC use was associated with decreased risk or recurrence (HR 0.62, p<0.01)Initial total costs over 5 years were higher in the BLC group ($108,411 vs $66,734; p<0.01), with outpatient costs being
More news about: Photocure
Dec 08, 2025, 00:01 ET Riyadh Air and IBM Partner to Launch World's First AI-Native Airline
Riyadh Air will introduce a personalized digital workplace powered by AI agents. The platform will give employees a single, chat-first entry point to HR, simplifying workflows and accelerating key employee and manager self-service capabilities as Riyadh Air doubles its workforce in the next 12 months.Crew
More news about: IBM
Dec 07, 2025, 22:54 ET 【直擊2025 ASH】亞盛醫藥Bcl-2抑制劑利生妥®治療維奈克拉經治髓系腫瘤患者的Ib/II期研究數據積極，全球競爭力持續顯現
44例可評估的復發/難治的AML/MPAL患者ORR為43.2%，完全緩解（CR）率為31.8%（14/44）。在可評估的22例既往接受過維奈克拉治療的R/R AML/MPAL患者中，ORR為31.8% (7/22)，CR率為22.7%（5/22）；15例可評估的初治HR MDS/CMML患者的ORR為80.0%，6例（40.0%）獲CR，6例（40.0%）獲骨髓CR（mCR）；R/R AML/MPAL或R/R HR MDS/CMML患者的中位總生存期分別為7.6個月和11.3個月；初治AML/MPAL或初治HR MDS/CMML患者的中位總生存期分別為6.3個月和未達到。安全性數據：第1部分劑量遞增階段及第2部分劑量拓展階段均未發生劑量限制性毒性（D
More news about: 亞盛醫藥
Dec 07, 2025, 16:30 ET Lilly's Jaypirca (pirtobrutinib) met its primary endpoint in first-of-its-kind, head-to-head Phase 3 study versus Imbruvica (ibrutinib)
at this analysis but was trending in favor of pirtobrutinib compared to ibrutinib in the ITT (HR=0.569 [95% CI, 0.388-0.834]), relapsed/refractory (HR=0.729 [95% CI, 0.471-1.128]), and treatment-naïve (HR=0.239 [95% CI, 0.098-0.586]) populations, with a median follow-up of 22.0 months, 18.4 months, and
More news about: Eli Lilly and Company
Dec 06, 2025, 15:00 ET Best HR and Payroll Software (2025): QuickBooks Awarded for Accuracy and Team Management by Better Business Advice
as the Best HR and Payroll Software (2025) for its accuracy, team management capabilities, and ease of use. The recognition reflects how essential reliable HR and payroll systems have become for organizations navigating a more complex regulatory and workforce environment. Best HR and Payroll
More news about: BetterBusinessAdvice.com
Dec 05, 2025, 23:30 ET Godrej Industries Group's Assistive Tech Conference promotes accessible and equitable workplaces in India
spotlighting the stories, contribution, and everyday strength of employees with disabilities across its operations.Vaibhav Ram, Global Head - HR, Godrej Consumer Products (GCPL), said, "At a time when disability employment in India remains far below its potential, GCPL is committed
More news about: Godrej Industries Group
Dec 05, 2025, 16:20 ET Johnson & Johnson's INLEXZO™ (gemcitabine intravesical system) delivers 74 percent disease-free survival at one year in BCG-unresponsive, high-risk, papillary-only NMIBC
compared to low-risk NMIBC.3,4 HR-NMIBC makes up 15-44 percent of patients with NMIBC and is characterized by a high-grade, large tumor size, presence of multiple tumors, and carcinoma in situ.5 Radical cystectomy is currently recommended for HR-NMIBC patients who fail BCG therapy, with
More news about: Johnson & Johnson
Dec 05, 2025, 08:00 ET Blueprint Medicines, a Sanofi Company, Highlights Long-Term Clinical Benefit of AYVAKIT® (avapritinib) Across Indolent and Advanced Systemic Mastocytosis at 2025 ASH Annual Meeting
demographic differences between the two patient populations.AYVAKIT was associated with improved OS relative to midostaurin (Hazard Ratio [HR]: 0.08; p<0.001) in these patients, who have traditionally had the worst prognosis.Data PresentationsOral
More news about: Blueprint Medicines, a Sanofi company
Dec 05, 2025, 06:47 ET HR Path espande la sua presenza nella regione Asia Pacifico (APAC) con l'acquisizione strategica di Blueprint HR Software
HR Path, leader globale nella consulenza HR e nelle soluzioni HRIS, annuncia l'acquisizione strategica di Blueprint HR Software Solutions, una controllata di Blueprint Technologies, società con sede in India specializzata in soluzioni SAP SuccessFactors, Concur e UKGPARIS,
More news about: HR Path